Ann: CannEpil Authorised to Commence Australian Sales, page-2

CannEpilTM available for Australian supply under Authorised Prescriber Scheme

First commercial-scale production and material revenues to commence from
MXC Investigational Medicinal Product (IMP)

• MXC’s Medicinal Cannabis based IMP, CannEpilTM is now available for supply in
Australia under the Authorised Prescriber Scheme

• Authorisation has been granted by the TGA to specialist prescribers who are now
authorised to supply CannEpilTM to patients in Australia

• Authorisation follows recent Human Research Ethics Committee endorsement
from St Vincent’s Hospital Melbourne for the use of CannEpilTM in the treatment
of adult patients with drug-resistant epilepsy

• Represents a major milestone for MXC, validating and confirming its seed-topharma
strategy with the start of commercial supply of its first IMP offering

• The Company expects this to initially generate $1 million in annualised revenue
from the initial base of approximately 100 patients

• CannEpilTM is expected to be available for supply in Australia by December 2018